Metrics as of 10/13/2026, 06:49 PM (Berlin time), refresh in progress.
SELLAS Life Sciences Group Stock
SELLAS Life Sciences Group, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Angelos Stergiou
- Employees
- 13
- Market cap
- $2 B
- IPO
- 12/03/2008
SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 antigen, and…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
SELLAS Life Sciences Group stock: price history
1D
-12.0%
1W
-14.3%
1M
-14.4%
6M
+91.2%
YTD
+164.7%
1Y
+362.0%
2Y
+698.4%
5Y
+13.0%
10Y
-99.9%
Next earnings date
Next earnings date
11/11/2026 (in 25 days)
Volatility around earnings
~13% stronger price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vsqueeze-release-v1.0 on 16/10/26. Not a buy or sell signal.Beta
What does this mean?
Volatility squeeze
BearishPrice swings had compressed unusually tight beforehand (volatility near a low) and are now releasing into a stronger move. Technical analysis views such tight phases as often preceding a bigger move.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about SELLAS Life Sciences Group
Analyst assessment of SELLAS Life Sciences Group
PRICE TARGET LOW
US$35.00
CONSENSUS
US$35.00
MEDIAN
US$35.00
PRICE TARGET HIGH
US$35.00
0
STRONG BUY
5
BUY
0
HOLD
0
SELL
0
STRONG SELL
5
TOTAL · Buy
As of: 12/03/2026
SELLAS Life Sciences Group stock metrics
P/E
-58.73
P/B
17.06
EV/EBITDA
-85.55
RETURN ON EQUITY
-7.0%
NET MARGIN
0.0%
DEBT/EQUITY
0.01
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
98.8%
FLOAT SHARES
183,788,511
AVG. DAILY VOLUME (30D)
6,063,587
Insider transactions (SEC)
Stergiou Angelos M.
Attention
11 mentions today in US forums, 1000% more than yesterdayPrice since yesterday: -12.0%
Forums (Reddit)
See the full forum history with Pro.
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about SELLAS Life Sciences Group stock
What does SELLAS Life Sciences Group do?
SELLAS Life Sciences Group, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Angelos Stergiou, the company employs around 13 people.
The IPO was on 12/03/2008; the stock trades on NASDAQ under the ticker SLS.
What do analysts say about SELLAS Life Sciences Group stock?
5 analysts rate the stock, the consensus is Buy (as of 12/03/2026).
The average price target is US$35.00, ranging from US$35.00 to US$35.00, with a median of US$35.00.
This is an external assessment, not a statement by Market Jury.
When does SELLAS Life Sciences Group report next?
The next earnings date is 11/11/2026.
Around past earnings, price swings were roughly 13% stronger than usual.
Does SELLAS Life Sciences Group pay a dividend?
No, SELLAS Life Sciences Group currently does not pay a dividend.
Which stocks are comparable to SELLAS Life Sciences Group?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get SELLAS Life Sciences Group stock analyzed?
Clicking "Analyze stock" lets five strategies assess SELLAS Life Sciences Group against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.